

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Susan WIMER-MACKIN

Application No.: *To Be Assigned* (U.S. Nat'l. Stage of PCT/US2005/004678) Group Art Unit: *To Be Assigned*

Filed: August 11, 2006

Examiner: *To Be Assigned*For: **Anthrax Antigens and Methods of Use**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97
and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of documents 16-57 cited in the attached Form PTO-1449 are enclosed.
- ☐ Copies of the remaining publications listed on the attached Form PTO-1449 are not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.:
to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
Should the Examiner be unable to locate a document, a copy will be provided upon request.

IAP11 Rec'd PCT/PTO 11 AUG 2006

- ☒ [x] No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98 because this application was filed after June 30, 2003.
- ☐ [] Documents _____ listed on the attached Form PTO-1449 were cited in a foreign search or examination report corresponding to _____ application serial no. _____ and mailed on _____, cited herein as document ____.
- ☐ [] Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ [] Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- ☐ [] Enclosed is an explanation of non-English publication(s) ____ for which an English translation is not available.
- ☒ [x] Documents 17-32 are non-English publications. Abstracts for document nos. 17-31 may be found within each publication. An English abstract of non-English document no. 32, SU 11789218 A1 attached to the end of the publication.
- ☐ [] The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.:

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ [] within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ [] within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ [x] before the mailing date of a first office action on the merits; or
- ☐ [] before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

PATENT

10/589290

Attorney Docket No. LIGO-009/02US

Application No. *To Be Assigned* (U.S.

Nat'l. Stage of PCT/US2005/004678)


Page 3

IAP11 Rec'd PCT/PTO 11 AUG 2006¹

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.

Respectfully submitted,
COOLEY GODWARD LLP

Dated: August 11, 2006

By: 
Bonnie Weiss McLeod
Reg. No. 43,255

USPTO Customer No. 58249

COOLEY GODWARD LLP

ATTN: Patent Group

The Bowen Building

875 15th Street, NW Suite 800

Washington, DC 20005-2221

Phone: (202) 842-7800

Fax: (202) 842-7899

INFORMATION DISCLOSURE CITATION				Attorney Docket No. LIGO-009/02US		Application No. <i>To Be Assigned</i>	
(Use several sheets if necessary) PTO Form 1449				Applicants: Susan WIMER-MACKIN PAGE 1 of 3			
				Filing Date: August 11, 2006		Group Art Unit: <i>To Be Assigned</i>	
U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1.	2003/0198651	Klimpel <i>et al.</i>				
	2.	2003/0118591	Levy				
	3.	4,172,126	Okonogi <i>et al.</i>				
	4.	4,436,727	Ribi				
	5.	4,436,728	Ribi <i>et al.</i>				
	6.	4,912,094	Myers <i>et al.</i>				
	7.	5,674,908	Haces <i>et al.</i>				
	8.	5,962,428	Carrano <i>et al.</i>				
	9.	6,197,755	Carrano <i>et al.</i>				
	10.	6,329,156	Cirino <i>et al.</i>				
	11.	6,348,450	Tang <i>et al.</i>				
	12.	6,387,665	Farchaus <i>et al.</i>				
	13.	6,592,872	Klimpel <i>et al.</i>				
	14.	6,602,510	Fikes <i>et al.</i>				
	15.	6,770,479	Lee <i>et al.</i>				
FOREIGN PATENT DOCUMENTS							
	Document No.	Date	Country	Class	Sub-Class	Translation	
	16.	AU 758019	Australia				
	17.	RU 1566532 C	Russia			Abstract	
	18.	RU 2056861 C1	Russia			Abstract	
	19.	RU 2095409 C1	Russia			Abstract	
	20.	RU 2112544 C1	Russia			Abstract	
	21.	RU 2115433 C1	Russia			Abstract	
	22.	RU 2123532 C1	Russia			Abstract	
	23.	RU 2141340 C1	Russia			Abstract	
	24.	RU 2142009 C1	Russia			Abstract	
	25.	RU 2142010 C1	Russia			Abstract	
	26.	RU 2151798 C1	Russia			Abstract	
	27.	RU 2180917 C1	Russia			Abstract	
	28.	RU 2181294 C2	Russia			Abstract	
	29.	RU 2181296 C2	Russia			Abstract	
	30.	RU 2191599 C1	Russia			Abstract	
	31.	RU 2198921 C2	Russia			Abstract	
Examiner			Date Considered				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Attorney Docket No. LIGO-009/02US		Application No. <i>To Be Assigned</i>			
				Applicants: Susan WIMER-MACKIN				PAGE 2 of 3	
				Filing Date: August 11, 2006		Group Art Unit: <i>To Be Assigned</i>			
FOREIGN PATENT DOCUMENTS									
		Document No.	Date	Country	Class	Sub-Class	Translation		
	32.	SU 1789218 A1	01/23/1993	Soviet Union			Derwent abstract attached		
	33.	WO 98/11914 A1	03/26/1998	WIPO					
	34.	WO 00/02522 A2	01/20/2000	WIPO					
	35.	WO 03/048390 A1	06/12/2003	WIPO					
	36.	WO 03/049670 A2	06/19/2003	WIPO					
	37.	WO 2004/004654 A2	01/15/2004	WIPO					
	38.	WO 2005/000884 A1	01/06/2005	WIPO					
	39.	WO 2005/007804 A2	01/27/2005	WIPO					
	40.	WO 2005/048918 A2	06/02/2005	WIPO					
	41.	WO 2005/068493 A1	07/28/2005	WIPO					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)									
	42.	Boyaka <i>et al.</i> , "Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen," <i>J. Immunol.</i> 170 :5636-5643 (2003).							
	43.	Chabot <i>et al.</i> , "Anthrax capsule vaccine protects against experimental infection," <i>Vaccine</i> 23 :43-47 (2004).							
	44.	Daubenspeck <i>et al.</i> , "Novel Oligosaccharide Side Chains of the Collagen-like Region of BclA, the Major Glycoprotein of the <i>Bacillus anthracis</i> Exosporium," <i>J. Biol. Chem.</i> 279 :30945-30953 (2004).							
	45.	Flick-Smith <i>et al.</i> , "Mucosal or Parenteral Administration of Microsphere-Associated <i>Bacillus anthracis</i> Protective Antigen Protects against Anthrax Infection in Mice," <i>Infect. Immunity</i> 70 :2022-2028 (2002).							
	46.	Gaur <i>et al.</i> , "Effect of nasal immunization with protective antigen of <i>Bacillus anthracis</i> on protective immune response against anthrax toxin," <i>Vaccine</i> 20 :2836-2839 (2002).							
	47.	Ivins <i>et al.</i> , "Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques," <i>Vaccine</i> 16 :1141-1148 (1998).							
	48.	Kozel <i>et al.</i> , "mAbs to <i>Bacillus anthracis</i> capsular antigen for immunoprotection in anthrax and detection of antigenemia," <i>Proc. Natl. Acad. Sci. USA</i> 101 :5042-5047 (2004).							
	49.	LaForce, "Anthrax," <i>Clin. Infect. Dis.</i> 19 :1009-1014 (1994).							
Examiner				Date Considered					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449		Attorney Docket No. LIGO-009/02US	Application No. <i>To Be Assigned</i>
		Applicants: Susan WIMER-MACKIN	
		PAGE 3 of 3	
		Filing Date: August 11, 2006	Group Art Unit: To Be Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
	50.	Miksza <i>et al.</i> , "Protective Immunization against Inhalational Anthrax : A Comparison of Minimally Invasive Delivery Platforms," <i>J. Infect. Dis.</i> 191 :278-288 (2005).	
	51.	Reynolds, "Modulating airway defenses against microbes," <i>Curr. Opin. Pulmonary Med.</i> 8 : 1 page abstract (2002)	
	52.	Rhie <i>et al.</i> , "A dually active anthrax vaccine that confers protection against both bacilli and toxins," <i>Proc. Natl. Acad. Sci. USA</i> 100 :10925-10930 (2003).	
	53.	Schneerson <i>et al.</i> , "Poly(γ -D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of <i>Bacillus anthracis</i> : A potential addition to the anthrax vaccine," <i>Proc. Natl. Acad. Sci. USA</i> 100 :8945-8950 (2003).	
	54.	Sigma-Aldrich, "MPL® + TDM Adjuvant System," 2 pages, Sigma-Aldrich (publication date unknown).	
	55.	Sylvestre <i>et al.</i> , "Polymorphism in the Collagen-Like Region of the <i>Bacillus anthracis</i> BclA Protein Leads to Variation in Exosporium Filament Length," <i>J. Bacteriol.</i> 185 :1555-1563 (2003).	
	56.	Sylvestre <i>et al.</i> , "A collagen-like surface glycoprotein is a structural component of the <i>Bacillus anthracis</i> exosporium,," <i>Mol. Microbiol.</i> 45 :169-178 (2002).	
	57.	Wimer-Mackin <i>et al.</i> , "An intranasal vaccine targeting both the <i>Bacillus anthracis</i> toxin and bacterium provides protection against aerosol spore challenge in rabbits," <i>Vaccine</i> 24 :3953-3963 (2006).	
Examiner		Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			